Treatment with octreotide LAR of the advanced neuroendocrine neoplasm of the pancreas with liver metastases — a case report

Abstract

A most frequent malignant tumour of the pancreas is adenocarcinoma. The pancreas can be also a primary site of neuroendocrine neoplasms of the digestive system, which are a heterogeneous group of tumors derived from various neuroendocrine cells scattered within the gastrointestinal tract. These tumors can be secretory active. Production of hormones by neuroendocrine neoplasms are responsible for determined for the occurrence of characteristic clinical symptoms, what in many cases steers the diagnostics process and facilitates the earlier diagnosis. In case of secretary active neuroendocrine neoplasms of the pancreas clinical symptoms can depend from the secretion of the insulin, the gastrin, the glucagon, vasoactive peptide and etc. The current paper presents the case report of 45-years old patient with neuroendocrine tumour of the pancreas with liver metastases as an example confirming the effectiveness of somatostatin analogues in the control of clinical, radiological and bio­chemical syndromes and also an example of indicative of the necessity of the exercise of the echocardiography for the purpose of the exclusion of heart complications (carcinoid syndrome) in dumb clinically cases on the side of the cardiovascular system.